HCAT

Health CatalystD

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.25

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.10

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.60

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment remains cautious-to-negative. Primary-source evidence supports a monitoring thesis, not a strong rebound call: profitability improved on an adjusted basis, but retention weakened, management withheld FY2026 guidance, and the leadership transition adds execution uncertainty while liquidity is materially lower than a year ago [#PR-2026-03-12] [#8-K-2026-04-03] [#10-K-2026-03-12].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQ1 2026 revenue and EBITDA against March outlookHigh impact

The nearest test is whether HCAT can deliver Q1 2026 revenue of $68-$70 million and adjusted EBITDA of $7-$8 million after Q4 revenue fell 6% year over year and dollar-based retention dropped to 93%; a clean print would help stabilize sentiment, but a miss would reinforce the ongoing reset [#PR-2026-03-12].

2026-08-06eventStrategic review and CEO-transition clarityHigh impact

Management is withholding full-year 2026 guidance during an internal strategic and operational review tied to the CEO transition, while the March 31 transition agreement keeps former CEO Daniel Burton as strategic advisor through December 31, 2026. Any update that restores guidance or clarifies cost actions and go-forward priorities could move the stock materially, but visibility remains limited today [#PR-2026-03-12] [#8-K-2026-04-03].

2027-03-12catalystTechnology-mix improvement must outweigh retention and liquidity pressureHigh impact

The longer-term setup depends on HCAT sustaining its shift toward technology revenue, which reached $208.3 million versus $102.9 million of professional services revenue in 2025, while preserving enough client retention and liquidity to work through Ignite migrations, TEMS downsell pressure, and covenant-bearing debt. The company ended 2025 with $95.7 million of cash, cash equivalents, and short-term investments, so execution matters more than narrative at this stage [#10-K-2026-03-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology